Making Tomorrow’s
Cancer Treatment Better

We are Isofol

Isofol is a publicly listed biotech company dedicated to developing arfolitixorin, a next-generation folate-based drug candidate designed to enhance the efficacy of standard treatments for patients with severe cancer.

Our goal is s to have a central impact on tomorrow’s cancer care – helping more patients respond better to their treatment, improve their prognosis, and gain more time with life.

Isofol’s shares are traded on Nasdaq Stockholm.